The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Analysis of plasma biomarker and tumor genetic alterations from a phase II trial of lenvatinib in patients with advanced endometrial cancer.
Yasuhiro Funahashi
Employment or Leadership Position - Eisai
Stock Ownership - Eisai
Richard T. Penson
Other Remuneration - Protocol Dev. Co.
Matthew A. Powell
Consultant or Advisory Role - Arno Therapeutics; Eisai; Genentech/Roche; GlaxoSmithKline; Novartis
Honoraria - Ethicon; Merck
David S. Miller
Consultant or Advisory Role - Eisai
Research Funding - Eisai
Jean Fan
Employment or Leadership Position - Eisai
Min Ren
Employment or Leadership Position - Eisai
Nicole Meneses
Employment or Leadership Position - Eisai
Pallavi Sachdev
Employment or Leadership Position - Eisai
Tadashi Kadowaki
Employment or Leadership Position - Eisai
Stock Ownership - Eisai
James P. O'Brien
Employment or Leadership Position - Eisai
Ignace Vergote
Consultant or Advisory Role - Eisai
Honoraria - Eisai